Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287512 | 0.79 | KMT2A (0.45) | GPR88KMT2APTGESALOX5MEN1 | |
| SCHEMBL6290236 | 0.74 | CCR5 (0.45) | KMT2AALDH1A1MEN1POLBTSHR | |
| SCHEMBL6290827 | 0.72 | MAPT (0.55) | HTR6KMT2AALDH1A1MEN1TSHR | |
| SCHEMBL23052531 | 0.72 | ALDH1A1 (0.54) | KMT2AALDH1A1MEN1POLBHPGD | |
| SCHEMBL6290237 | 0.72 | HTR6 (0.40) | HTR6KMT2ACPB1ALDH1A1MEN1 | |
| SCHEMBL6122390 | 0.71 | ALDH1A1 (0.61) | KMT2APTGESALOX5ALDH1A1POLB | |
| SCHEMBL4789668 | 0.70 | ALDH1A1 (0.49) | KMT2AALDH1A1MEN1POLBTSHR | |
| SCHEMBL7652738 | 0.68 | ESR1 (0.55) | KMT2AALDH1A1POLBTSHRHPGD | |
| SCHEMBL21456816 | 0.68 | KMT2A (0.43) | HTR6GPR88KMT2AALDH1A1MEN1 | |
| SCHEMBL7533916 | 0.67 | HTR6 (0.38) | HTR6KMT2AALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872716-B2 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | WU XINHE (US) | 2004-11-25 | — | — | US | disclosed |
| US-6703383-B2 | HETEROCYCLIC COMPOUNDS COMPRISING A SULFONAMIDE GROUP TO TREAT DISEASES SUCH AS PSYCHOLOGICAL DISORDERS CAUSED BY ONE OR MORE PROTEIN-G COUPLED RECEPTORS OR LIGAND -GATED ION CHANNELS | SEPRACOR, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002022579-A2 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | TRPV1, CNR2, TRPM5 | HTR6 231/4885GPR88 113/4885KMT2A 1488/4885 |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | TRPV1, CNR2, TRPM5 | HTR6 231/4885GPR88 113/4885KMT2A 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.